190 related articles for article (PubMed ID: 36242618)
21. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
22. Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection.
Zhu L; Xue H; Sun Z; Li P; Qian T; Xing X; Li N; Zhao Y; Wu W; Jin Z
J Magn Reson Imaging; 2017 Dec; 46(6):1648-1655. PubMed ID: 28419614
[TBL] [Abstract][Full Text] [Related]
23. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
24. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
25. Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K; Delrue L; Lambert B; Makar A; Lambein K; Denys H; Tummers P; Van den Broecke R; Villeirs G; De Meerleer G
Int J Gynecol Cancer; 2012 May; 22(4):630-7. PubMed ID: 22237382
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
27. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.
Soriano A; Castells A; Ayuso C; Ayuso JR; de Caralt MT; Ginès MA; Real MI; Gilabert R; Quintó L; Trilla A; Feu F; Montanyà X; Fernández-Cruz L; Navarro S
Am J Gastroenterol; 2004 Mar; 99(3):492-501. PubMed ID: 15056091
[TBL] [Abstract][Full Text] [Related]
28. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the determination of the local tumor extent of primary endometrial cancer using clinical examination and 3 Tesla magnetic resonance imaging compared to histopathology.
Brocker KA; Radtke JP; Hallscheidt P; Sohn C; Schlemmer HP; Alt CD
Arch Gynecol Obstet; 2019 May; 299(5):1391-1398. PubMed ID: 30719553
[TBL] [Abstract][Full Text] [Related]
30. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
Okada KI; Kawai M; Hirono S; Kojima F; Tanioka K; Terada M; Miyazawa M; Kitahata Y; Iwahashi Y; Ueno M; Hayami S; Murata SI; Shimokawa T; Yamaue H
Langenbecks Arch Surg; 2020 Feb; 405(1):23-33. PubMed ID: 31993737
[TBL] [Abstract][Full Text] [Related]
31. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT.
Park HS; Lee JM; Choi HK; Hong SH; Han JK; Choi BI
J Magn Reson Imaging; 2009 Sep; 30(3):586-95. PubMed ID: 19711405
[TBL] [Abstract][Full Text] [Related]
32. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
Mortensen MB
Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria.
Hong SB; Lee SS; Kim JH; Kim HJ; Byun JH; Hong SM; Song KB; Kim SC
Radiology; 2018 Dec; 289(3):710-718. PubMed ID: 30251929
[TBL] [Abstract][Full Text] [Related]
34. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
[TBL] [Abstract][Full Text] [Related]
35. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
36. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
Barreto SG; Loveday B; Windsor JA; Pandanaboyana S
ANZ J Surg; 2019 May; 89(5):481-487. PubMed ID: 30117669
[TBL] [Abstract][Full Text] [Related]
37. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
38. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.
Seufferlein T; Hammel P; Delpero JR; Macarulla T; Pfeiffer P; Prager GW; Reni M; Falconi M; Philip PA; Van Cutsem E
Cancer Treat Rev; 2019 Jul; 77():1-10. PubMed ID: 31163334
[TBL] [Abstract][Full Text] [Related]
39. Differentiation of pancreatic ductal adenocarcinoma from inflammatory mass: added value of magnetic resonance elastography.
Liu Y; Wang M; Ji R; Cang L; Gao F; Shi Y
Clin Radiol; 2018 Oct; 73(10):865-872. PubMed ID: 29895389
[TBL] [Abstract][Full Text] [Related]
40. Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the "target sign" by diffusion weighted imaging.
Ahlawat S; Fayad LM
Eur J Radiol; 2018 May; 102():195-201. PubMed ID: 29685535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
